Evaluation of Dihydropyrimidine Dehydrogenase Activity on Capecitabine Efficacy in Breast Cancer Patients

The primary objective of this study is to evaluate the impact of **DPD activity** on the efficacy of **capecitabine** in patients with **breast cancer**. Understanding the relationship between DPD activity and capecitabine efficacy is clinically relevant as it may influence treatment outcomes and guide personalized therapy approaches for breast cancer patients. The study aims to provide insights into optimizing capecitabine use by considering individual variations in DPD activity, potentially improving therapeutic efficacy and minimizing adverse effects.

The clinical trial involves participants diagnosed with **breast cancer**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion or exclusion criteria have been specified. The sponsor has not given further details on the general health status of the participants.

The clinical trial is designed to evaluate the impact of **DPD activity** on the efficacy of capecitabine in patients with **breast cancer**. The study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know which treatment the participants are receiving, thus minimizing bias. The trial commenced on July 16, 2020, and is projected to conclude by January 16, 2030, encompassing a total duration of approximately ten years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to confirm the diagnosis of breast cancer and to ensure that participants meet all necessary inclusion criteria while not falling under any exclusion criteria. Following successful screening, participants will be randomly assigned to either the treatment or control group.

Throughout the trial, participants will attend regular follow-up visits, which are scheduled to monitor their health status, assess treatment efficacy, and record any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The frequency and specific procedures of these follow-up visits will be determined by the study protocol, ensuring consistent data collection and participant safety.

The end-of-study visit marks the final assessment of participants, where comprehensive evaluations will be conducted to gather final data on treatment outcomes and any long-term effects. The expected length of participant involvement in the study is contingent upon the individual treatment plan and response, but it generally spans the entire duration of the trial unless early termination is warranted. Conditions that may lead to early termination include significant adverse reactions, withdrawal of consent, or any other medical or ethical reasons as determined by the study investigators.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental medication's maximum daily dose, maximum total dose, or maximum treatment period. Furthermore, there is no information on whether the medication is a **paediatric formulation** or an **orphan drug**. The trial's main objective and full title are also not provided in the data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 9, indicating an advanced stage of clinical research. The estimated recruitment start date was July 16, 2020, with an anticipated end date of January 16, 2030. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's impact. The trial's duration and phase suggest a comprehensive approach to evaluating the intervention's effectiveness, potentially involving various methodologies and tools to ensure robust and reliable results.